---
type: source
title: "ARPA-H EVIDENT Initiative: $139.4M for Behavioral Health Innovation Including $50M Psychedelic Research Matching"
author: "ARPA-H / HHS"
url: https://arpa-h.gov/news-and-events/arpa-h-announces-first-research-teams-139-million-initiative-transform-behavioral
date: 2026-04-24
domain: health
secondary_domains: []
format: government-announcement
status: processed
processed_by: vida
processed_date: 2026-05-11
priority: medium
tags: [ARPA-H, behavioral-health, psychedelics, psilocybin, federal-funding, mental-health, research]
intake_tier: research-task
extraction_model: "anthropic/claude-sonnet-4.5"
---

## Content

**Initiative name:** Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT)

**Total funding:** Up to $139.4 million

**Psychedelic research component:**
- At least $50 million allocated to match qualifying state government investments in psychedelic research for serious mental illness populations
- This is the federal matching mechanism from Trump's April 18, 2026 EO on psychedelics
- Texas IMPACT consortium ($50M state) + ARPA-H federal match ($50M) = ~$100M total for ibogaine research
- Diamond Therapeutics (Toronto): contributing Phase 2a psilocybin data for generalized anxiety disorder (GAD)
- University of Wisconsin: contributing data from 3 approved psilocybin trials

**EVIDENT initiative goals:**
- Generate FDA-ready clinical endpoints for rapid-acting behavioral health therapies
- Modalities: digital interventions, neuromodulation, neuroplastogens (including psychedelics)
- Selected team: INVI MindHealth (Denver) — real-time biomarker platform for neuromodulation + psychedelic therapies
- Future award announcements on rolling basis

**Context from Trump EO (April 18, 2026):**
- FDA Commissioner directed to issue National Priority Vouchers to psychedelics with Breakthrough Therapy designations
- DEA directed to initiate rescheduling reviews upon Phase 3 completion
- Right to Try pathway established for investigational psychedelics
- ARPA-H directed to match state psychedelic research investments

**ARPA-H vs. NIH distinction:** ARPA-H operates on a DARPA-like model — time-limited, mission-driven, tolerant of risk. Unlike NIH RO1 grants, ARPA-H can fund teams to produce specific regulatory-ready endpoints. This is the right instrument for accelerating psychedelic clinical data to FDA-ready quality.

## Agent Notes
**Why this matters:** The EVIDENT initiative represents the first systematic federal investment in psychedelic-assisted therapy research through a dedicated vehicle designed to produce FDA-ready evidence. This changes the research funding landscape: psychedelic research is transitioning from private pharmaceutical funding (Compass, Usona) and philanthropy (MAPS, Multidisciplinary Association for Psychedelic Studies) to government-backed infrastructure. $139.4M is not enormous by NIH standards, but ARPA-H's mandate to produce FDA endpoints makes each dollar more leveraged than typical research grants.

**What surprised me:** Diamond Therapeutics (Canadian company) being selected for a US government research initiative. Psilocybin research is genuinely international, and ARPA-H is incorporating non-US data into the US regulatory pathway. Also: the GAD indication for Diamond's trial — generalized anxiety disorder (GAD) is even larger than TRD or PTSD. If psilocybin works for GAD, the addressable population is massive.

**What I expected but didn't find:** Any digital mental health component. Despite the EVIDENT title covering "digital interventions," the announced research teams are all pharmacological/neuromodulation. The digital mental health access gap (the KB's existing claim) is not being addressed by EVIDENT.

**KB connections:**
- [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]] — ARPA-H EVIDENT is focused on producing clinical evidence, not closing the access gap. Supply-side (evidence) investment without addressing demand-side (reimbursement) gap.
- [[AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate]] — EVIDENT's "FDA-ready endpoints" focus is an attempt to reduce trial failure rates through better endpoint design

**Extraction hints:**
- This source is better as context/evidence for a broader claim about federal psychedelic research infrastructure than as a standalone claim
- Flag for extractor: the GAD indication (Diamond Therapeutics) is new to the KB — GAD has ~40M US sufferers, the largest single anxiety disorder. If psilocybin works for GAD, the access debate becomes even more acute
- Note: EVIDENT does NOT address the reimbursement bottleneck — it produces clinical evidence that CMS would use to make coverage decisions. The pipeline is: ARPA-H evidence → FDA approval → CMS review → reimbursement. EVIDENT only accelerates the first step.

**Context:** Official ARPA-H announcement, confirmed by HHS.gov press release. Published April 24, 2026 — same day as Compass Priority Voucher announcement, suggesting coordinated rollout from Trump's April 18 EO. High-confidence source.

## Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]
WHY ARCHIVED: Documents the federal government's first systematic investment vehicle for psychedelic-assisted therapy research. EVIDENT is producing the clinical evidence pipeline that, if successful, enables CMS coverage decisions 3-5 years out. Important for understanding the structural pathway from research to access.
EXTRACTION HINT: Don't over-claim this as "closing the mental health gap" — EVIDENT is a research infrastructure investment, not a care delivery intervention. The gap between research funding and patient access remains the structural problem. Use as context for the regulatory pathway analysis.
